Get the Stockscreener App
216.00
4.21%
-9.50
After Hours:
215.13
-0.87
-0.40%
Insulet Corporation stock is traded at $216.00, with a volume of 1.14M.
It is down -4.21% in the last 24 hours and down -12.95% over the past month.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
See More
Previous Close:
$225.50
Open:
$225.69
24h Volume:
1.14M
Relative Volume:
1.19
Market Cap:
$15.21B
Revenue:
$2.71B
Net Income/Loss:
$247.10M
P/E Ratio:
61.70
EPS:
3.5008
Net Cash Flow:
$349.90M
1W Performance:
-6.20%
1M Performance:
-12.95%
6M Performance:
-33.25%
1Y Performance:
-20.79%
1-Day Range:
$215.26
$227.24
1-Week Range:
$215.26
$232.18
52-Week Range:
$215.26
$354.88
Insulet Corporation Stock (PODD) Company Profile
Name
Insulet Corporation
Sector
Industry
Phone
978-600-7000
Address
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
216.00 | 15.87B | 2.71B | 247.10M | 349.90M | 3.5008 |
ABT
Abbott Laboratories
|
104.83 | 180.82B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.65 | 125.72B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.89 | 111.16B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
69.78 | 101.28B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.67 | 47.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Resumed | TD Cowen | Hold |
| Jan-12-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-16-25 | Initiated | Evercore ISI | Outperform |
| Nov-19-25 | Upgrade | UBS | Neutral → Buy |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Resumed | Oppenheimer | Outperform |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| May-13-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-29-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-06-25 | Initiated | RBC Capital Mkts | Outperform |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-07-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-21-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-04-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-02-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-21-23 | Upgrade | Citigroup | Neutral → Buy |
| Aug-21-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-19-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Jul-28-20 | Initiated | Wells Fargo | Overweight |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-03-20 | Initiated | BofA/Merrill | Neutral |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-10-19 | Initiated | CFRA | Sell |
| Oct-23-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-14-19 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-04-19 | Downgrade | UBS | Buy → Neutral |
| Oct-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-06-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-06-19 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-20-18 | Initiated | Berenberg | Buy |
| Feb-22-18 | Reiterated | Barclays | Overweight |
| Jan-08-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-03-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Sep-15-17 | Initiated | Barclays | Overweight |
View All
Insulet Corporation Stock (PODD) Latest News
Published on: 2026-03-26 06:50:47 - baoquankhu1.vn
Insulet (NASDAQ:PODD) Hits New 12-Month LowShould You Sell? - MarketBeat
Insulet stock faces securities fraud probe pressure after Omnipod 5 pod recall and sharp NASDAQ decl - AD HOC NEWS
Insulet slides as investors weigh Omnipod 5 device correction and potential 2026 costs - Quiver Quantitative
Insulet Corp. stock underperforms Wednesday when compared to competitors - MSN
Insulet Corporation stock hits 52-week low at $216.12 - Investing.com
PODD Investor Alert: Insulet Corp. Potential Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Device Defect - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Insulet Corporation (PODD) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Assenagon Asset Management S.A. Buys 24,761 Shares of Insulet Corporation $PODD - MarketBeat
Insulet stock faces pressure amid investor probe and recent share pullback on NASDAQ - AD HOC NEWS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet CorporationPODD - ChartMill
Insulet OmniPod 5 Recall Lawsuits May Be Filed Over Problems Resulting in Diabetic Ketoacidosis, Hospitalization and Death - AboutLawsuits.com
Is Insulet stock underperforming the Dow? - MSN
PODD SEC FilingsInsulet Corp 10-K, 10-Q, 8-K Forms - Stock Titan
M & L Capital Management Ltd Purchases Shares of 5,630 Insulet Corporation $PODD - MarketBeat
Insulet Corporation (PODD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Gradient Investments LLC Purchases 10,497 Shares of Insulet Corporation $PODD - MarketBeat
Insulet Corporation $PODD Shares Bought by Nordea Investment Management AB - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Insulet Corporation (PODD) And Encourages Stockholders to Reach Out - ACCESS Newswire
Insulet Corporation $PODD Shares Sold by Swiss Life Asset Management Ltd - MarketBeat
Insulet Stock Faces Headwinds Amid Diabetes Tech Slowdown and Market Pressures - AD HOC NEWS
Hudson Bay Capital Management LP Takes Position in Insulet Corporation $PODD - MarketBeat
Insulet recalling certain defective Omnipod insulin delivery devices - MSN
Is Insulet's Stock Lagging Behind the Dow? - Bitget
Insulet (PODD) down 8.2% since last earnings report: Can it rebound? - MSN
Is Insulet Stock Underperforming the Dow? - Barchart.com
Understanding Momentum Shifts in (PODD) - Stock Traders Daily
Should You Continue to Hold Insulet Stock in Your Portfolio? - TradingView
Insulet (PODD) Down 8.2% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Insulet Corp. Hits New 52-Week Low at $216.51 Amid Market Challenges - Markets Mojo
Assessing Insulet (PODD) Valuation After Omnipod 5 Tubing Defect And Ongoing Product Replacements - Sahm
PODD Investor Alert: Insulet Corp. Potential Securities - GlobeNewswire
Insulet Corporation $PODD Shares Sold by JPMorgan Chase & Co. - MarketBeat
Alecta Tjanstepension Omsesidigt Increases Stake in Insulet Corporation $PODD - MarketBeat
Securities Fraud Investigation Into Insulet Corporation (PODD) Co - The National Law Review
Securities Fraud Investigation Into Insulet Corporation (PODD) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - The AI Journal
FinancialContentInsulet Corporation (PODD) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - FinancialContent
Insulet Gains 62.9% in a Year: What's Driving the Stock? - MSN
Insulet Corp. Stock Hits Day Low of $216.51 Amid Price Pressure - Markets Mojo
Volatility Watch: Can Insulet Corporation deliver alpha2026 Action & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
ATTENTION Insulet Corporation (PODD) Investors: Possible FraudContact Levi & Korsinsky Today - The Globe and Mail
Momentum Shift: Does Insulet Corporation stock benefit from AI growth2026 Big Picture & Community Verified Trade Alerts - baoquankhu1.vn
Insulet Corp. stock underperforms Friday when compared to competitors - MSN
Insulet Surges 2.19% as Earnings and Buys Outweigh Recall Risks Traded at 448th Volume Rank - Bitget
Insulet recalls specific Omnipod 5 insulin pump lots after injuries - Investing.com Nigeria
Insulet stock (ISIN: US45784P1012): Insulin Pump Maker Faces Competitive Pressure Amid Rising Health - AD HOC NEWS
Insulet to spend up to $40M on insulin pump recall - Worcester Business Journal
Jain Global LLC Purchases 63,719 Shares of Insulet Corporation $PODD - MarketBeat
Insulet Stock Drops 7% After Omnipod 5 Recall - TIKR.com
Insulet Corporation Stock (PODD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):